Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00227461

Enrollment

Registered

2005-09-28

Start date

2005-09-30

Completion date

2021-12-31

Last updated

2021-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphasia, Stroke

Keywords

Aphasia, Stroke

Brief summary

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

Detailed description

In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.

Interventions

DRUGWait first, then levetiracetam

Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.

DRUGLevetiracetam first, then wait

subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Stroke * Aphasia * Can give consent

Exclusion criteria

* Renal failure * Pregnancy * Other neurological condition

Design outcomes

Primary

Measure	Time frame
Speech and language assessment	6 months - 1year

Secondary

Measure	Time frame
Memory assessment	6 months to 1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026